Latest News

The initiative recognizes that pharmacists serve as critical figures in healthcare, often representing the first and most accessible point of contact for millions of Egyptians seeking guidance on everyday health concerns.

The partnership seeks to unify healthcare data and convert it into actionable insights that healthcare providers, insurance companies, and government agencies can leverage.

The facility provides a full range of primary care services, from acute conditions and chronic disease management to preventive health, all delivered in a calm, private clinical environment.

Jeito II will back between 15 and 20 clinical-stage biopharma companies, primarily in Europe, with average investments of up to €150 million (USD180 million) per company

Since launching in 2024, AI Airlock has grown steadily, moving beyond its initial pilot phase to tackle increasingly complex regulatory questions.

EverSea Medicines will make an initial payment of US$150 million at closing, followed by two additional payments of US$50 million each, scheduled for the first quarters of 2028 and 2029, subject to agreed conditions.

Implementing these programs under Africa CDC leadership will enhance disease surveillance systems, expand laboratory infrastructure, and foster deeper partnerships with leading European research institutions.

Lenacapavir complements existing prevention methods such as oral pre-exposure prophylaxis and long-acting injectable cabotegravir.

The hospital’s construction was originally scheduled to begin in 2024, with the first phase of the 500-bed facility targeted for completion in December 2025.

The contract includes multiyear options that could ultimately deliver up to USD 482 million if exercised, enabling Shionogi to establish a dedicated manufacturing facility in the United States.